Genetic researchers map different migraine types in hunt for new treatment

A new international research study has generated promising results for the development of migraine therapies.

Photo: Christin Klose/AP/Ritzau Scanpix

For 20 years, migraine treatments have focused solely on one symptom of the condition – the headache.

Now, a new international study can help drug developers target the other symptoms, according to the genetic researcher and contributor to the study, Thomas Folkmann Hansen, who leads the research group for neurological genetic research at Danish hospital Rigshospitalet.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs